Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Optimaliseren follow-upstrategie na fertiliteitsparende chirurgie voor cervixcarcinoom
jan 2024 | Gynaecologische oncologie